10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2015

OR

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from               to                     .

Commission file number: 001-31573

Medifast, Inc.

(Exact name of registrant as specified in its charter)

Delaware	13-3714405
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

3600 Crondall Lane
Owings Mills, Maryland 21117
Telephone Number: (410) 581-8042

Indicate by checkmark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x    No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes x    No ¨

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, or a non-accelerate filer. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12 b-2 of the Exchange Act.

Large accelerated filer ¨      Accelerated filer x       Non-accelerated filer ¨          Smaller reporting company o

Indicate by checkmark whether the Registrant is a shell company (as defined in Rule 12 b-2 of the Exchange Act).

Yes ¨    No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

The number of shares of the registrant’s common stock outstanding at May 11, 2015 was 12,124,699.

Medifast, Inc. and subsidiaries

Index

Part 1 – Financial Information:
Item 1 – Financial Statements
Condensed Consolidated Balance Sheets as of March 31, 2015 (unaudited) and  December 31, 2014 (audited)	3
Condensed Consolidated Statements of Income (unaudited) for the Three Months Ended  March 31, 2015 and 2014	4
Condensed Consolidated Statements of Comprehensive Income (unaudited) for the Three  Months Ended March 31, 2015 and 2014	5
Condensed Consolidated Statements of Changes in Stockholders’ Equity (unaudited) for the  Three Months Ended March 31, 2015	6
Condensed Consolidated Statements of Cash Flows (unaudited) for the Three Months Ended March 31, 2015 and 2014	7
Notes to Unaudited Condensed Consolidated Financial Statements	8
Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations	15
Item 3 – Quantitative and Qualitative Disclosures about Market Risk	20
Item 4 – Controls and Procedures	20
Part II – Other Information:
Item 1 – Legal Proceedings	20
Item 1.A – Risk Factors	21
Item 5 – Other Information	21
Item 6 – Exhibits	22

2

Item 1. Financial Statements

MEDIFAST, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

	(Unaudited)		(Audited)
	March 31, 2015		December 31, 2014
ASSETS
Current assets:
Cash and cash equivalents	$	33,423,000	$	24,459,000
Accounts receivable-net of allowance for sales returns and doubtful accounts of $397,000 and $354,000		2,306,000		1,650,000
Inventory		14,186,000		15,735,000
Investment securities		27,955,000		28,185,000
Income taxes, prepaid		3,897,000		5,099,000
Prepaid expenses and other current assets		2,814,000		2,875,000
Deferred tax assets		2,978,000		3,727,000
Current assets of discontinued operations		18,000		184,000
Total current assets		87,577,000		81,914,000
Property, plant and equipment - net		32,507,000		33,477,000
Other assets		162,000		497,000
Long-term assets of discontinued operations		19,000		22,000
TOTAL ASSETS	$	120,265,000	$	115,910,000
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued expenses	$	25,468,000	$	21,854,000
Current maturities of capital leases		234,000		232,000
Current liabilities of discontinued operations		2,348,000		4,858,000
Total current liabilities		28,050,000		26,944,000
Other liabilities:
Capital leases, net of current portion		183,000		242,000
Deferred tax liabilities		5,493,000		5,492,000
Long-term liabilities of discontinued operations		1,712,000		2,756,000
Total liabilities		35,438,000		35,434,000
Stockholders' Equity:
Common stock; par value $.001 per share; 20,000,000 shares authorized; 12,391,652 and 12,365,690 issued 12,124,699 and 12,075,764 issued and outstanding		12,000		12,000
Additional paid-in capital		951,000		1,132,000
Accumulated other comprehensive income		523,000		435,000
Retained earnings		83,341,000		78,897,000
Total stockholders' equity		84,827,000		80,476,000
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	120,265,000	$	115,910,000

The accompanying notes are an integral part of these consolidated financial statements.

3

MEDIFAST, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

	Three Months Ended March 31,
	2015		2014
Revenue	$	73,364,000	$	79,233,000
Cost of sales		19,594,000		21,309,000
Gross Profit		53,770,000		57,924,000
Selling, general, and administrative		47,258,000		48,313,000
Income from operations		6,512,000		9,611,000
Other income
Interest and dividend income, net		132,000		135,000
Other income		148,000		184,000
		280,000		319,000
Income from continuing operations before income taxes		6,792,000		9,930,000
Provision for income taxes		2,376,000		3,385,000
Income from continuing operations		4,416,000		6,545,000
Income (loss) from discontinued operations, net of tax		28,000		(578,000	)
Net income	$	4,444,000	$	5,967,000
Basic earnings per share
Earnings per share from continuing operations	$	0.36	$	0.49
Earnings (Loss) per share from discontinued operations	$	0.00	$	(0.04	)
Earnings per share	$	0.36	$	0.45
Diluted earnings per share
Earnings per share from continuing operations	$	0.36	$	0.49
Earnings (Loss) per share from discontinued operations	$	0.00	$	(0.04	)
Earnings per share	$	0.36	$	0.45
Weighted average shares outstanding -
Basic		12,108,202		13,160,294
Diluted		12,196,794		13,248,156

The accompanying notes are an integral part of these consolidated financial statements.

4

MEDIFAST, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)

	Three Months Ended March 31,
	2015			2014
Net income	$	4,444,000		$	5,967,000
Other comprehensive income, net of tax
Change in unrealized gains/losses on marketable securities:
Change in fair value of marketable securities, net of tax		175,000			103,000
Adjustment for net (gains)/losses realized and included in net income, net of tax		(87,000	)		(91,000	)
Total change in unrealized (gains)/losses on marketable securities, net of tax		88,000			12,000
Other comprehensive income		88,000			12,000
Comprehensive income	$	4,532,000		$	5,979,000

The accompanying notes are an integral part of these consolidated financial statements.

5

MEDIFAST, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

Three Months Ended March 31, 2015

(Unaudited)

	Number of Shares Issued		Par Value $0.001 Amount		Additional Paid- In Capital			Retained Earnings		Accumulated other comprehensive income		Total
Balance, December 31, 2014		12,365,690	$	12,000	$	1,132,000		$	78,897,000	$	435,000	$	80,476,000
Shares issued to executives and directors		25,962
Share-based compensation						529,000							529,000
Net shares repurchased for employee taxes						(875,000	)						(875,000	)
Share-based compensation tax benefit						165,000							165,000
Net income									4,444,000				4,444,000
Net change in unrealized gain on investments											88,000		88,000
Balance, March 31, 2015		12,391,652	$	12,000	$	951,000		$	83,341,000	$	523,000	$	84,827,000

The accompanying notes are an integral part of these consolidated financial statements.

6

MEDIFAST, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Three Months Ended March 31,
	2015			2014
Cash flows from operating activities:
Net income	$	4,444,000		$	5,967,000
Income (loss) from discontinued operations, net of tax		28,000			(578,000	)
Income from continuing operations		4,416,000			6,545,000
Adjustments to reconcile net income to net cash provided by operating activities from continuing operations:
Depreciation and amortization		1,877,000			2,029,000
Realized (gain) loss on investment securities, net		(118,000	)		(188,000	)
Share-based compensation		529,000			774,000
Deferred income taxes		(154,000	)		(381,000	)
(Gain) on disposal of fixed assets		-			(32,000	)
Changes in assets and liabilities which provided (used) cash:
Accounts receivable		(656,000	)		(204,000	)
Inventory		1,549,000			2,120,000
Prepaid expenses and other current assets		16,000			(67,000	)
Other assets		335,000			2,000
Accounts payable and accrued expenses		3,615,000			(82,000	)
Income taxes		1,202,000			610,000
Net cash provided by operating activities- continuing operations		12,611,000			11,126,000
Net cash used in operating activities- discontinued operations		(2,513,000	)		(505,000	)
Net cash provided by operating activities		10,098,000			10,621,000
Cash Flow from Investing Activities:
Sale of investment securities		2,022,000			3,572,000
Purchase of investment securities		(1,526,000	)		(7,943,000	)
Purchase of property and equipment		(907,000	)		(1,182,000	)
Net cash used in investing activities- continuing operations		(411,000	)		(5,553,000	)
Net cash used in investing activities- discontinued operations		-			(42,000	)
Net cash used in investing activities		(411,000	)		(5,595,000	)
Cash Flow from Financing Activities:
Repayment of long-term debt and capital leases		(57,000	)		(55,000	)
Decrease in note receivable		45,000			7,000
Net shares repurchased for employee taxes		(875,000	)		-
Excess tax benefits from share-based compensation		165,000			-
Net cash used in financing activities- continuing operations		(722,000	)		(48,000	)
Net cash used in financing activities- discontinued operations		-			-
Net cash used in financing activities		(722,000	)		(48,000	)
NET CHANGE IN CASH AND CASH EQUIVALENTS		8,965,000			4,978,000
Cash and cash equivalents - beginning of the period		24,459,000			36,382,000
Cash and cash equivalents - end of period	$	33,424,000		$	41,360,000
Supplemental disclosure of cash flow information:
Interest paid	$	10,000		$	53,000
Income taxes paid	$	295,000		$	2,687,000

The accompanying notes are an integral part of these consolidated financial statements.

7

Medifast, Inc. and subsidiaries

Notes to Unaudited Condensed Consolidated Financial Statements

General

1. Basis of Presentation

The condensed unaudited interim consolidated financial statements included herein have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”), without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). However, in the opinion of management, all adjustments consisting of normal, recurring adjustments considered necessary for a fair presentation of the financial position and results of operations have been included. The condensed consolidated financial statements and notes are presented as permitted on Form 10-Q. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading.

The results of operations for the three months ended March 31, 2015 are not necessarily indicative of results that may be expected for the year ending December 31, 2015. The accompanying condensed unaudited interim consolidated financial statements should be read in conjunction with the 2014 audited financial statements and notes thereto, which are included in the Company’s Annual Report on Form 10-K, as amended, filed with the SEC for the year ended December 31, 2014 (“2014 Form 10-K”).

2. Presentation of Financial Statements

The Company’s condensed consolidated financial statements include the accounts of Medifast, Inc. and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.

3. Recent Accounting Pronouncements

We have considered all new accounting pronouncements and have concluded that there are no new pronouncements that may have a material impact on our results of operations, financial condition, or cash flows, based on current information, except for:

ASU 2014-09, Revenue from Contracts with Customers (Topic 606), requires the Company to recognize revenue for the transfer of goods or services to customers for the amount the Company expects to be entitled in exchange for those goods or services. The Company will be required to identify the contract, identify the relevant performance obligations, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when the entity satisfies a performance obligation. The provisions of this ASU are effective for interim and annual periods beginning after December 15, 2016; however, the Financial Accounting Standards Board has proposed delaying the effective date to annual periods beginning after December 15, 2017. Management is currently evaluating the effect that the provisions of ASU 2014-12 will have on the Company’s financial statements.

ASU 2014-08, Presentation of Financial Statements (Topic 205) and Property Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, raises the threshold for a disposal to qualify as a discontinued operation and requires new disclosures of both discontinued operations and certain other disposals that do not meet the definition of a discontinued operation. It is effective for annual periods beginning on or after December 15, 2014. The Company elected early option of the pronouncement and accounted for the discontinued operations of the Medifast Corporate Weight Control Center channel in accordance with these guidelines.

4. Revenue Recognition

Revenue is recognized net of discounts, rebates, promotional adjustments, price adjustments, and estimated returns and upon transfer of title and risk to the customer which primarily occurs at shipping (F.O.B. terms). Upon shipment, the Company has no further performance obligations and collection is reasonably assured as the majority of sales are paid for prior to shipping.

5. Inventories

Inventories consist principally of packaged meal replacements held in the Company’s warehouses. Inventory is stated at the lower of cost or market, utilizing the first-in, first-out method. The cost of finished goods includes the cost of raw materials, packaging supplies, direct and indirect labor and other indirect manufacturing costs. On a quarterly basis, management reviews inventory for unsalable or obsolete inventory.

8

Inventories consisted of the following at March 31, 2015 and December 31, 2014:

	2015			2014
Raw Materials	$	3,692,000		$	4,410,000
Packaging		1,105,000			920,000
Non-food Finished Goods		879,000			1,108,000
Finished Goods		8,817,000			9,689,000
Reserve for Obsolete Inventory		(307,000	)		(392,000	)
	$	14,186,000		$	15,735,000

6. Earnings per Share

Basic earnings per share (“EPS”) computations are calculated utilizing the weighted average number of shares of common stock outstanding during the periods presented. Diluted EPS is calculated utilizing the weighted average number of shares of common stock outstanding adjusted for the effect of dilutive common stock equivalents.

The following table sets forth the computation of basic and diluted EPS for the three months ended March 31:

	Three Months Ended March 31,
	2015		2014
Numerator:
Income from continuing operations	$	4,416,000	$	6,545,000
Income (loss) from discontinued operations		28,000		(578,000	)
Net income	$	4,444,000	$	5,967,000
Denominator:
Weighted average shares of common stock outstanding		12,108,202		13,160,294
Effect of dilutive common stock equivalents		88,592		87,862
Weighted average shares of common stock outstanding		12,196,794		13,248,156
EPS:
Basic earnings per share
Earnings per share from continuing operations	$	0.36	$	0.49
Earnings (loss) per share from discontinued operations	$	0.00	$	(0.04	)
Earnings per share	$	0.36	$	0.45
Diluted earnings per share
Earnings per share from continuing operations	$	0.36	$	0.49
Earnings (loss) per share from discontinued operations	$	0.00	$	(0.04	)
Earnings per share	$	0.36	$	0.45

The calculation of diluted earnings per share excluded 79,925 and 59,542 options outstanding for the three months ended March 31, 2015 and 2014, respectively, that could potentially dilute base earnings per share in the future.

7. Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

8. Financial Instruments

Certain financial assets and liabilities are accounted for at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The following fair value hierarchy prioritizes the inputs used to measure fair value:

9

Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2 – Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies.

Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value from the perspective of a market participant.

The following table represents cash and the available-for-sale securities adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category recorded as cash and cash equivalents or investment securities as of March 31, 2015 and December 31, 2014:

10

	March 31, 2015
	Cost		Unrealized Gains		Unrealized Losses			Accrued Interest		Estimated Fair Value		Cash & Cash Equivalents		Investment Securities
Cash	$	32,242,000	$	-	$	-		$	-	$	32,242,000	$	32,242,000	$	-
Level 1:
Money Market Accounts		1,181,000		-		-			-		1,181,000		1,181,000		-
Mutual Funds		10,508,000		124,000		(99,000	)		-		10,533,000		-		10,533,000
Corporate Equity Securities		3,785,000		709,000		(51,000	)		-		4,443,000		-		4,443,000
Government & Agency Securities		4,396,000		68,000		(1,000	)		10,000		4,473,000		-		4,473,000
		19,870,000		901,000		(151,000	)		10,000		20,630,000		1,181,000		19,449,000
Level 2:
Municipal Bonds		3,448,000		73,000		(7,000	)		21,000		3,535,000		-		3,535,000
Corporate Bonds		4,880,000		65,000		(4,000	)		30,000		4,971,000		-		4,971,000
		8,328,000		138,000		(11,000	)		51,000		8,506,000		-		8,506,000
Total	$	60,440,000	$	1,039,000	$	(162,000	)	$	61,000	$	61,378,000	$	33,423,000	$	27,955,000

	December 31, 2014
	Cost		Unrealized Gains		Unrealized Losses			Accrued Interest		Estimated Fair Value		Cash & Cash Equivalents		Investment Securities
Cash	$	23,894,000	$	-	$	-		$	-	$	23,894,000	$	23,894,000	$	-
Level 1:
Money Market Accounts		565,000		-		-			-		565,000		565,000		-
Mutual Funds		10,733,000		63,000		(129,000	)		-		10,667,000		-		10,667,000
Corporate Equity Securities		3,408,000		695,000		(31,000	)		-		4,072,000		-		4,072,000
Government & Agency Securities		4,559,000		49,000		(5,000	)		15,000		4,618,000		-		4,618,000
		19,265,000		807,000		(165,000	)		15,000		19,922,000		565,000		19,357,000
Level 2:
Municipal Bonds		3,652,000		78,000		(7,000	)		28,000		3,751,000		-		3,751,000
Corporate Bonds		5,022,000		29,000		(12,000	)		38,000		5,077,000		-		5,077,000
		8,674,000		107,000		(19,000	)		66,000		8,828,000		-		8,828,000
Total	$	51,833,000	$	914,000	$	(184,000	)	$	81,000	$	52,644,000	$	24,459,000	$	28,185,000

The Company had realized gains of $118,000 and $188,000 for the three months ended March 31, 2015 and 2014, respectively.

11

9. Shared-based Compensation

Stock Options:

The Company has issued non-qualified and incentive stock options to employees and nonemployee directors. The fair value of these options are estimated on the date of grant using the Black-Scholes option pricing model, which requires estimates of the expected term of the option, the expected volatility of the price of the Company’s common stock, dividend yield and the risk-free interest rate. Options outstanding as of March 31, 2015 vest over a period of three years with an expiration term of ten years. The exercise price of these options ranges from $24.26 to $31.55. The expected volatility is based on the historical volatility of the Company’s common stock over the period of time equivalent to the expected term for each award. Due to the Company’s lack of option exercise history, the expected term is calculated using the simplified method defined as the midpoint between the vesting period and the contractual term of each award. The risk free interest rate is based on the U.S. Treasury yield curve in effect on the date of grant which most closely corresponds to the expected term of the option. The Company historically has not issued dividends and therefore does not utilize a dividend yield in the calculation. The weighted average input assumptions used and resulting fair values were as follows:

	2015			2014
Expected life (in years)		6			6
Risk-free interest rate		1.72	%		1.61	%
Expected volatility		52.69	%		63.15	%
Dividend yield		-			-

The following table summarizes the stock option activity:

	Shares		Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Life (Yrs)		Aggregate Intrinsic Value
Outstanding at December 31, 2014		67,375	$	26.05
Granted		53,500		31.55
Exercised		-		-
Forfeited		-		-
Expired		-		-
Outstanding at March 31, 2015		120,875	$	28.49		9.20		264,084
Exerciseable at March 31, 2015		36,281	$	26.29		8.68		137,633

The weighted-average grant date fair value of options granted was $16.00. The unrecognized compensation expense calculated under the fair value method for shares expected to vest as of March 31, 2015 was approximately $1.3 million and is expected to be recognized over a weighted average period of 2.5 years.

Restricted Stock:

The Company has issued restricted stock to employees and nonemployee directors generally with terms up to five years. The fair value is equal to the market price of the Company’s common stock on the date of grant. Expense for restricted stock is amortized ratably over the vesting period. The following table summarizes the restricted stock activity:

	Shares			Weighted-Average Grant Date Fair Value
Unvested at December 31, 2014		333,676		$	25.31
Granted		8,980			31.55
Vested		(75,703	)		25.08
Forfeited		-			-
Unvested at March 31, 2015		266,953		$	25.59

The total costs of the options and restricted awards vested and charged against income during the three months ended March 31, 2015 and 2014 was $530,000 and $774,000, respectively. The Company accrued an additional $349,000 and $338,000 for performance awards for the three months ended March 31, 2015 and 2014, respectively. The cost of the 2015 awards will depend on the Company’s fiscal 2015 performance and will be finalized and approved at the first Board of Directors meeting in 2016. The cost recognized during the quarter is based on the performance that management expects the Company will achieve as of March 31, 2015. The total income tax benefit recognized in the consolidated statements of income for these restricted stock awards was approximately $210,000 and $243,000 for the three months ended March 31, 2015 and 2014, respectively. The total tax benefit recognized in additional paid-in capital upon vesting of restricted stock awards for the three months ended March 31, 2015 was $165,000. No tax benefit was recognized in additional paid-in capital upon vesting of the restricted stock awards in the three months ended March, 31 2014. There was approximately $5.4 million of total unrecognized compensation cost related to restricted stock awards as of March 31, 2015. The cost is expected to be recognized over a weighted-average period of approximately 2.7 years.

12

10. Business Segments

Operating segments are components of an enterprise about which separate financial information is available that is regularly reviewed by the chief operating decision maker about how to allocate resources and in assessing performance. The consolidated operating profit of the Company is reviewed by the chief operating decision maker as a single segment and sales are reviewed at the channel level.

The following table presents sales by channel for the three months ended March 31, 2015 and 2014:

	2015		2014
Medifast Direct	$	14,426,000	$	17,144,000
Take Shape For Life		52,102,000		56,966,000
Medifast Weight Control Centers- Franchise		4,681,000		3,588,000
Medifast Wholesale		2,155,000		1,535,000
Net Revenue	$	73,364,000	$	79,233,000

11. Contingencies

The Company filed a civil complaint on February 17, 2010 in the U.S. District Court (SD, Cal) against Barry Minkow and the Fraud Discovery Institute, Inc. (collectively, “Minkow”), iBusiness Reporting, and its editor William Lobdell, Tracy Coenen and Sequence, Inc. (collectively, “Coenen”), “Zee Yourself”, and Robert L. Fitzpatrick (“FitzPatrick”) for defamation, market manipulation and unfair business practices, alleging a scheme of market manipulation of Medifast stock for Defendants’ for monetary gain, and damaging the business reputation of Medifast and its Take Shape For Life division. Bradley T. MacDonald, former Executive Chairman of Medifast and a stockholder, joined the lawsuit individually.  The lawsuit seeks $270 million in compensatory damages, punitive damages, and ancillary relief.  In March 2011, the District Court granted in part and denied in part certain Anti-SLAPP Motions to Strike (i.e. motions to dismiss) previously filed by all Defendants.  The Company appealed that portion of the District Court’s ruling which dismissed its defamation claims against Minkow and Coenen in the 9th Circuit Court of Appeals.  Defendant FitzPatrick’s motion was denied as to the Company’s defamation claim, and FitzPatrick appealed that portion of the Court’s ruling.  On June 4, 2014, the Panel of the 9th Circuit Court of Appeals issued a decision, denying FitzPatrick’s appeal and remanding to the District Court for further consideration; reversing the District Court’s decision as to Minkow and remanding for further consideration; denying MacDonald’s appeal in its entirety; and denying Medifast’s appeal as to Coenen.  On September 26, 2014, the District Court obtained jurisdiction of the case once again and the parties set a briefing schedule on the outstanding issues remanded by the Ninth Circuit. Coenen filed a motion for attorneys’ fees, which Medifast has opposed. The Court issued an Order on the motion, granting it in part and denying it in part, on March 24, 2015. Judgment was entered on behalf of Coenen on April 21, 2015.

The Company entered into guarantee agreements with two key franchisee partners in order to support them obtaining additional funding to expand their business into new markets. This is in line with the Company’s long-term strategy of expanding the franchise business utilizing knowledgeable franchise partners. The loans associated with these agreements have been paid in full. The first guarantee provides financial coverage for a $1.0 million loan and a $1.0 million line of credit. The variable rate term loan has a 2 year term expiring in September 2015; payment calculations assume a 7 year amortization with a balloon payment due at the end of the term. The line of credit has a two year term expiring in September 2015. The franchisee associated with these loans failed to pay the monthly obligations and the Company paid off the loans in April 2015. The Company is a secondary guarantor on the loan and line of credit and has pursued personal recourse against the franchise owner. The second guarantee provides financial coverage for a $1.4 million loan and was paid in full in March 2015. The variable rate term loan has a 2 year term expiring in October 2015; payment calculations assume a 7 year amortization with a balloon payment due at the end of the term. The Company is the third guarantor on these loans and has recourse against another entity owned by the franchisee and the franchisee owner(s) themselves should it be deemed necessary.

12. Discontinued Operations, Exit Activities, and Clinic Obligations

In 2014, the Company exited the MWCC corporate center model by selling 41 centers to existing franchise partners (24 centers were sold in June 2014 and the remaining 17 centers were sold in December 2014) and closing the remaining 34 corporate centers. In accordance with ASU 2014-08, Presentation of Financial Statements (Topic 205) and Property Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity the assets, liabilities, operating results, and cash flows of the MWCC corporate center channel have been presented separately as discontinued operations in the Consolidated Financial Statements for all periods presented.

The following is a summary of the Company’s operating results for discontinued operations for the three months ended March 31, 2015 and 2014:

13

	2015		2014
Revenue	$	-	$	7,296,000
Income/(loss) before income taxes from discontinued operations		45,000		(924,000	)
Income tax/(benefit) provision		17,000		(346,000	)
Income/(loss) from discontinued operations, net of tax	$	28,000	$	(578,000	)

The following table presents the aggregate carrying amounts of the major classes of assets and liabilities divested as of March 31, 2015 included in discontinued operations:

	2015
ASSETS
Current assets:
Receivables, net	$	14,000
Inventory		-
Prepaid expenses and other current assets		4,000
Total current assets		18,000
Other assets		19,000
Total assets	$	37,000
LIABILITIES
Current liabilities:
Accounts payable and accrued expenses	$	2,348,000
Total current liabilities		2,348,000
Long-term lease obligations		1,712,000
Total liabilities	$	4,060,000

The following table summarizes the exit obligations primarily closed clinic lease obligations, severance accruals, and customer refunds incurred as of March 31, 2015:

14

Ending accrued balance as of December 31, 2014	$	6,534,000
Charges incurred during the period		-
Adjustments recorded during the period (1)		(549,000	)
Payments during the period		(2,042,000	)
Ending accrued balance as of March 31, 2015	$	3,943,000

(1)- The adjustments to the accrual recorded in the first quarter of 2015 relate primarily to favorable termination agreements reached with landlords of closed Corporate Medifast Weight Control Centers.

These charges were recorded in the balance sheet as of March 31, 2015 as follows:

Total current liabilities of discontinued operations	$	2,231,000
Total long-term liabilities of discontinued operations		1,712,000
Ending accrued balance as of December 31, 2014	$	3,943,000

13. Stockholders’ Rights Plan

On August 28, 2014, the Company adopted a stockholders’ rights plan whereby the Board of Directors authorized and declared a dividend distribution of one right for each outstanding share of common stock of the Company to the stockholders of record at the close of business on September 9, 2014. The rights are not presently exercisable and remain attached to the shares of common stock until the occurrence of certain triggering events. The rights will expire on August 28, 2015, unless exercised, redeemed, or exchanged prior to that time. The Board of Directors may terminate the rights plan before the expiration date.

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

FORWARD LOOKING STATEMENTS

Special Note Regarding Forward-Looking Statements

This report contains information that may constitute “forward-looking statements.” Generally, the words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “project,” “will,” and similar expressions identify forward-looking statements, which generally are not historical in nature. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future – including statements relating to future operating results- are forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those in our Annual Report on Form 10-K for the year ended December 31, 2014 (the “Form 10-K”), and those described from time to time in our future reports filed with the Securities and Exchange Commission.

The following discussion should be read in conjunction with the unaudited condensed consolidated financial statements and related notes appearing elsewhere herein.

Overview

Medifast, Inc. (“Medifast,” the “Company,” “we,” “us,” or “our”) is engaged in the production, distribution, and sale of weight loss and weight management products and services and other consumable health and diet products. The Company’s product lines include weight loss and weight management products, meal replacements, and vitamins. Customers of our independent contractor health coaches (“Health Coaches”) in the Take Shape For Life person-to-person direct sales channel are directed to order our products through either the internet or through the Company’s in-house call center. Our product sales accounted for 97% of our revenues in the first three months of 2015 and 98% of our revenues in the first three months of 2014. Revenue consists primarily of meal replacement food sales. In the first three months of 2015, total revenue decreased to $73.4 million compared to $79.2 million in the first three months of 2014, a decrease of $5.8 million or 7.3%. The decline was due to a decrease in revenue in the Take Shape For Life and Medifast Direct channels offset by improvements in the Franchise Medifast Weight Control Centers (“MWCC”) and Medifast Wholesale channels as described in the “Overview of Results of Operations” section. The Take Shape For Life sales channel accounted for 71.0%, the Medifast Direct channel accounted for 19.7%, the Franchise MWCC channel accounted for 6.4%, and the Medifast Wholesale channel accounted for 2.9% of total revenue. See Note 10, “Business Segments” of the notes to the financial statements for a detailed breakout of revenues of the Company’s business channels.

15

We review and analyze a number of key operating and financial metrics to manage our business, including revenue to advertising spend, number of active Health Coaches and average monthly revenue generated per health coach in the Take Shape For Life channel.

In 2014, the Company exited the MWCC corporate center model by selling 41 centers to existing franchise partners and closing the remaining 34 corporate centers. The assets, liabilities, operating results, and cash flows of the MWCC corporate center channel have been presented separately as discontinued operations in the Consolidated Financial Statements for all periods presented.

Sales Channels

Medifast Direct – In the direct-to-consumer channel (“Medifast Direct”), customers order Medifast product directly through the Company’s website, www.medifastnow.com or our in-house call center. This business is driven by a multi-media customer acquisition and retention strategy that includes both national and regional television, print, radio, digital advertising, direct mail, and email as well as public relations, word of mouth referrals, and social media initiatives. The Medifast Direct division focuses on targeted marketing initiatives to acquire and retain customers and provides support through its on-line community and its in-house call center and nutrition support team of registered dietitians to better serve its customers.

Take Shape For Life™ – Take Shape For Life, a Code of Ethics member of the Direct Selling Association, is the one-on-one health coaching division and the largest business unit of Medifast. This health coaching network consists of Independent Health Coaches, who are trained to provide coaching and support to clients on Medifast weight-loss products and programs. The role of the Independent Health Coach is two-fold:

1. To provide support and coaching to help clients successfully reach a healthy weight and adopt a healthy lifestyle.

2. To help mentor and grow other Health Coaches in their teams to become thriving independent entrepreneurs.

Take Shape For Life provides a road map and tools to empower the clients and Health Coaches to take control of their health and to achieve an optimal life through the balance of body, mind, and finances.

Franchise Medifast Weight Control Centers – Franchise Medifast Weight Control Centers is the brick and mortar clinic channel of Medifast.

In 2008, Medifast Franchise Systems, Inc. (“MFSI”), a subsidiary of Medifast, began offering the center model as a franchise opportunity. MFSI currently has MWCC franchised centers located in Arizona, California, Louisiana, Minnesota, Maryland, Pennsylvania, Texas, Virginia and Wisconsin. As of March 31, 2015, 70 MWCC franchise centers were in operation.

Medifast Wholesale- The Medifast Wholesale channel enters into contracts with physicians and other distributing companies to sell Medifast products to their customers. Since 1980, over 20,000 doctors have recommended Medifast products and programs to their patients as a medically-proven solution to control their weight and improve their health. Medifast medical provider practices carry an inventory of wholesale products and resell them to patients while providing appropriate medical monitoring, testing, and support to ensure healthy weight loss.

The Company offers extensive resources to assist the providers, their staff and their patients in achieving success with their program. Medifast medical providers have access to marketing assets and training modules to help the practice grow their program and enable patients to achieve their weight loss and associated health goals. Medifast’s nutrition support team includes registered dietitians and a behavioral specialist who provide program support and advice via phone and email.

Critical Accounting Policies and Estimates

Our consolidated financial statements are prepared in accordance with GAAP. Our significant accounting policies are described in Note 2 of the consolidated financial statements included in the Form 10-K.

The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Management develops, and changes periodically, these estimates and assumptions based on historical experience and on various other factors that it believes to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. The accounting estimates we consider critical include revenue recognition, impairment of fixed assets and intangible assets, income taxes, reserves for returns, operating leases and clinic closure costs.

During the three months ended March 31, 2015, we did not make any material changes to our critical accounting policies.

16

Overview of Results of Operations

	Three Months Ended March 31,
	2015			2014			$ Change			% Change
Revenue	$	73,364,000		$	79,233,000		$	(5,869,000	)		-7	%
Cost of sales		19,594,000			21,309,000			(1,715,000	)		-8	%
Gross Profit		53,770,000			57,924,000			(4,154,000	)		-7	%
Selling, general, and administrative costs		47,258,000			48,313,000			(1,055,000	)		-2	%
Income from operations		6,512,000			9,611,000			(3,099,000	)		-32	%
Other income
Interest income, net		132,000			135,000			(3,000	)		-2	%
Other income		148,000			184,000			(36,000	)		-20	%
		280,000			319,000			(39,000	)		-12	%
Income from continuing operations before income taxes		6,792,000			9,930,000			(3,138,000	)		-32	%
Provision for income tax expense		2,376,000			3,385,000			(1,009,000	)		-30	%
Income from continuing operations		4,416,000			6,545,000			(2,129,000	)		-33	%
Income (Loss) from discontinued operations, net of tax		28,000			(578,000	)		606,000			-105	%
Net income	$	4,444,000		$	5,967,000		$	(1,523,000	)		-26	%
% of revenue
Gross Profit		73.3	%		73.1	%
Selling, general, and administrative costs		64.4	%		61.0	%
Income from Operations		8.9	%		12.1	%

Revenue: Revenue decreased approximately 7.3% to approximately $73.4 million for the three months ended March 31, 2015 as compared to approximately $79.2 million for the three months ended March 31, 2014. The Take Shape For Life sales channel accounted for 71.0%, the Medifast Direct channel accounted for 19.7%, the Franchise MWCC channel accounted for 6.4%, and the Medifast Wholesale channel accounted for 2.9% of total revenue. The revenue to spend for the first quarter 2015 was 13.4-to-1 compared to 13.6-to-1 for 2014. Total advertising spend was $5.5 million in the first quarter of 2015 versus $5.8 million in the first quarter of 2014, a decrease of $0.3 million or 16.8%.

For the three months ended March 31, 2015, Take Shape For Life revenue decreased 9% to $52.1 million compared to $57.0 million in 2014. The decline in revenue for Take Shape For Life was driven by a decrease in the number of Health Coaches and revenue per Health Coach. Active Health Coaches were previously defined as Health Coaches earning income from a product sale in the last month of the quarter. However, in order to provide a more accurate depiction of the number of Health Coaches contributing to Take Shape For Life revenues, the Company will begin reporting a new active Health Coach count and average revenue per active Health Coach. The Health Coach count will now be reported as the number of earning coaches each quarter instead of the number of earning Health Coaches in the last month of the quarter. The average revenue per Health Coach will now be calculated on a quarterly basis instead of an average month within the quarter. These new quarterly measurements provide a more consistent metric for quarterly comparison.

17

The new and historical metrics for the prior periods are as follows:

Reporting	New Active Health		Historical Active		New Revenue per		Historical Revenue
Period	Coaches		Health Coaches		Health Coach		per Health Coach
Q1 2015		12,100		10,500	$	4,316	$	1,564
Q4 2014		11,700		9,300	$	3,896	$	1,401
Q3 2014		12,400		10,200	$	4,025	$	1,565
Q2 2014		12,400		10,800	$	4,347	$	1,596
Q1 2014		12,700		11,100	$	4,488	$	1,626
Q4 2013		12,800		10,500	$	4,047	$	1,477
Q3 2013		13,500		11,700	$	4,149	$	1,650
Q2 2013		13,200		11,800	$	4,656	$	1,710
Q1 2013		12,600		11,300	$	4,709	$	1,720

Using the new metrics, the number of active Health Coaches at the end of the first quarter of 2015 decreased to 12,100 compared with 12,700 during the same period for 2014, a decrease of 5.0%. However, the Company did experienced Health Coach growth from the fourth quarter of 2014, an increase of 400 Health Coaches. The revenue per Health Coach decreased 4% to $4,316 in the first quarter of 2015 compared to $4,488 in the first quarter of 2014 and increased $420 from the fourth quarter of 2015.

Medifast Direct revenue decreased 16% to $14.4 million for the three months ended March 31, 2015 compared to the same period for 2014. Revenues in this channel are driven primarily by targeted customer advertising on-line, via email and direct mail campaigns, and by highlighting customer successes in large national publications and on television. Sales are down year-over-year as new customer acquisition continues to be difficult. First quarter results were in-line with the Company’s expectations as we continue to focus on efficiently managing the investment of additional dollars into marketing.

Franchise MWCC channel revenue increased 31% year-over-year, with revenue of $4.7 million in 2015 compared to $3.6 million in 2014. The year-over-year increase in revenue was driven by the conversion of corporate centers over to franchise centers partially offset by franchise center closures as well as a decrease in sales of franchise centers open greater than one year. 70 franchise centers were in operation as of March 31, 2015, compared to 49 franchise centers as of March 31, 2014. From the first quarter of 2014 to the first quarter of 2015, 41 corporate centers were transitioned to the franchise model, however 7 of these centers subsequently closed during the same period. In addition, 13 centers that were open for more than 1 year were closed during the period.

Medifast Wholesale revenue increased $0.7 million, to $2.2 for the three months ended March 31, 2015 compared to $1.5 million for the three months ended March 31, 2014. The increase was primarily driven by an increase in activity within a few specific accounts for the quarter.

Costs of Sales: Cost of sales decreased approximately $1.7 million to $19.6 million for the three months ended March 31, 2015 compared to the same period in 2014. The decrease in cost of sales for the periods was primarily due to improved manufacturing efficiencies and decreased volume. As a percentage of sales, gross margin increased to 73.3% from 73.1% in the first quarter of 2015 versus the prior year. The gross margin improvement was the result of a price increase during the quarter and efficiencies in the supply chain.

Selling, General and Administrative Costs: Selling, general and administrative expenses were $47.3 million for the three months ended March 31, 2015 compared to $48.3 million in the same period of 2014. As a percentage of sales, selling, general and administrative expenses increased to 64.4% versus 61.0% in the first quarter of 2014. The Company incurred $1.8 million in extraordinary legal expenses related to 13D filings during the quarter. Excluding those expenses, selling, general, and administrative costs would have been $45.5 million, or 61.9%. Take Shape For Life commission expense, which is variable based upon product sales, decreased by approximately $2.4 million for the three months ended March 31, 2015 as TSFL sales declined 9% compared to the prior year.

Salaries and benefits increased by approximately $0.1 million in the first quarter of 2015 compared to the same period in 2014. The increase for the period was driven by an increase in bonuses offset by decreases in stock compensation expense, contract labor expense and medical insurance expense.

Sales and marketing expense decreased by $0.2 million in the first quarter of 2015 compared to same period in 2014. The decrease is the result of lower advertising spending and decreased costs associated with the annual Take Shape For Life incentive trip. These cost reductions were offset by the production costs incurred for the new Medifast commercials that aired during the first quarter of 2015.

General expenses increased $1.5 million for the three months ended March 31, 2015 in comparison to the same period in 2014. The quarterly increase was driven by $1.8 million in extraordinary legal expenses resulting from 13D filings. The Company reached a settlement agreement with Engaged Capital, LLC., a stockholder of the Company, during the first quarter and does not anticipate incurring additional expenses. The costs were offset by a decrease in consulting fees, general office expenses, and legal expenses excluding the costs of the 13D filings. Other expenses decreased by $0.1 million for the three months ended March 31, 2015. The decrease in expenses for the periods was the result reduced credit card fees resulting from decreased sales, a reduction in depreciation expense offset by an increase in licenses and fees.

18

Income taxes: In the first quarter of 2015, the Company recorded $2.4 million in income tax expense, an effective rate of 35.0%, compared to $3.4 million in income tax expense, an effective rate of 34.1% in the first quarter of 2014. The increase in the effective tax rate for the first quarter of 2015 in comparison to 2014 was primarily due to the reduction in the permanent difference of the domestic manufacturer deduction deriving from reduced income year-over-year and the timing of the recognition of the Corporate MWCC closure costs for tax purposes. The Company anticipates a full year tax rate of approximately 34-35% in 2015.

Income from continuing operations: Income from continuing operations was $4.4 million in the first quarter of 2015 compared to $6.5 million in the first quarter of 2014, a decrease of $2.1 million. Pre-tax profit as a percent of sales increased to 9.3% in the first quarter of 2015 compared to 12.5% in the first quarter of 2014. The decrease in income is a result of the reduced sales and the extraordinary legal expenses resulting from 13D filings. Excluding the extraordinary legal expenses, income from continuing operations would have been $5.6 million or $0.46 per diluted share.

Income from discontinued operations: In 2014, the Company exited the MWCC corporate center model by selling 41 centers to existing franchise partners and closing the remaining 34 corporate centers. The Company had minimal income from discontinued operations in 2015 from the settlement of lease agreements offset by incremental closure costs incurred during the quarter.

Net income: Net income was $4.4 million for the three months ended March 31, 2015 compared to $6.0 million for the three months ended March 31, 2014. The year-over-year change was driven by the factors described above in the explanations from continuing operations and loss from discontinued operations.

Liquidity and Capital Resources

The Company had stockholders’ equity of $84.9 million and working capital of $59.5 million on March 31, 2015 compared with $80.5 million and $55.0 million at December 31, 2014. The $4.5 million net increase in stockholder’s equity includes $4.4 million in net income from 2015 as the other equity transactions outlined in the “Condensed Consolidated Statement of Changes in Stockholders’ Equity”. The Company’s cash and cash equivalents position increased from $24.5 million at December 31, 2014 to $33.4 million at March 31, 2015.

In the three months ended March 31, 2015 the Company generated cash flow of $12.6 million from continuing operations, partially attributable to $4.4 million in income from continuing operations. Cash provided by operating activities of $9.1 million primarily include a $3.6 million increase in accounts payable and accrued expenses, depreciation and amortization of $1.9 million, a $1.5 million decrease in inventory, a $1.2 million decrease in prepaid income taxes, share based compensation of $0.5 million, and a $0.3 million decrease in other assets. This was offset by cash used by operating activities of $0.9 million which includes a $0.7 million increase in accounts receivable, a $0.2 million deferred income tax benefit, and $0.1 million realized gain on investment securities.

Net cash used in operating activities from discontinued operations was $2.5 million primarily including a $3.6 million decrease in accounts payable and accrued expenses. The use of cash was offset by a $0.1 million decrease in inventory and a $0.9 million of deferred income benefit.

In the three months ended March 31, 2015, net cash used in investing activities from continuing operations was $0.4 million, which was due to $1.5 million for the purchase of investment securities offset by $2.0 million of cash generated by the sale of investment securities and $0.9 million for the purchase of property and equipment.

In the three months ended March 31, 2015, financing activities used $0.7 million in cash including $0.9 million for net shares repurchased for employee taxes and net cash generated of $0.2 million for excess tax benefits from share-based compensation.

In pursuing its business strategy, the Company may require additional cash for operating and investing activities. The Company expects future cash requirements, if any, to be funded from operating cash flow and financing activities.

The Company has an undrawn, unsecured, revolving $5 million line of credit with Bank of America. The line of credit will expire on August 1, 2015, at which point the Company expects to extend the term or pursue other financing opportunities.

On August 28, 2014, the Company adopted a stockholders’ rights plan whereby the Board of Directors authorized and declared a dividend distribution of one right for each outstanding share of common stock of the Company to the stockholders of record at the close of business on September 9, 2014. The rights are not presently exercisable and remain attached to the shares of common stock until the occurrence of certain triggering events. The rights will expire on August 28, 2015, unless exercised, redeemed, or exchanged prior to that time. The Board of Directors may terminate the rights plan before the expiration date.

The Company evaluates acquisitions from time to time as presented.

Off-Balance Sheet Arrangements

In the past, the Company entered into guarantee agreements for the benefit of key franchisee partners in order to support them obtaining additional funding to expand their business into new markets.

The first guarantee provides financial coverage for a $1.0 million loan and a $1.0 million line of credit. The variable rate term loan has a 2 year term expiring in September 2015; payment calculations assume a 7 year amortization with a balloon payment due at the end of the term. The line of credit has a two year term expiring in September 2015. The franchisee associated with these loans has failed to pay the monthly obligations and the Company paid off the loans in April 2015, which was fully accrued as of December 31, 2014. The Company is a secondary guarantor on the loan and line of credit and has pursued personal recourse against the franchise owner.

The Company also provided a guarantee for a $1.4 million loan for another franchisee. This loan was paid off by the franchisee during the quarter and is no longer a potential exposure for the Company.

19

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Market risk is the potential loss arising from adverse changes in market rates and prices, such as interest rates and a decline in the stock market. The Company does not enter into derivatives, foreign exchange transactions or other financial instruments for trading or speculative purposes. The Company has an undrawn and unsecured revolving line of credit for $5,000,000, should it choose to draw on this line of credit in the future it would be subject to market risk due to changing interest rates.

The Company is exposed to market risk related to changes in interest rates and market pricing impacting our investment portfolio. Its current investment policy is to maintain an investment portfolio consisting mainly of U.S. money market and high-grade corporate securities, directly or through managed funds. Its cash is deposited in and invested through highly rated financial institutions in North America. Its marketable securities are subject to interest rate risk and market pricing risk and will fall in value if market interest rates increase or if market pricing decreases. If market interest rates were to increase and market pricing were to decrease immediately and uniformly by 10% from levels at March 31, 2015, it estimates that the fair value of its investment portfolio would decline by an immaterial amount and therefore it would not expect its operating results or cash flows to be affected to any significant degree by the effect of a change in market conditions on our investments.

There have been no material changes to our market risk exposure since March 31, 2015.

Item 4. Controls and Procedures

Management, including our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, as of March 31, 2015. Our disclosure controls and procedures are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported accurately and on a timely basis. Based on this evaluation performed in accordance with the criteria established in the 2013 Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission, our management concluded that the Company’s disclosure controls and procedures are effective of the reasonable assurance level as of the end of the period covered by this report.

Changes in Internal Control over Financial Reporting:

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the fiscal quarter ended March 31, 2015 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Part II Other Information

Item 1. Legal Proceedings

The Company filed a civil complaint on February 17, 2010 in the U.S. District Court (SD, Cal) against Barry Minkow and the Fraud Discovery Institute, Inc. (collectively, “Minkow”), iBusiness Reporting, and its editor William Lobdell, Tracy Coenen and Sequence, Inc. (collectively, “Coenen”), “Zee Yourself”, and Robert L. Fitzpatrick (“FitzPatrick”) for defamation, market manipulation and unfair business practices, alleging a scheme of market manipulation of Medifast stock for Defendants’ for monetary gain, and damaging the business reputation of Medifast and its Take Shape For Life division. Bradley T. MacDonald, former Executive Chairman of Medifast and a stockholder, joined the lawsuit individually.  The lawsuit seeks $270 million in compensatory damages, punitive damages, and ancillary relief.  In March 2011, the District Court granted in part and denied in part certain Anti-SLAPP Motions to Strike (i.e. motions to dismiss) previously filed by all Defendants.  The Company appealed that portion of the District Court’s ruling which dismissed its defamation claims against Minkow and Coenen in the 9th Circuit Court of Appeals.  Defendant FitzPatrick’s motion was denied as to the Company’s defamation claim, and FitzPatrick appealed that portion of the Court’s ruling.  On June 4, 2014, the Panel of the 9th Circuit Court of Appeals issued a decision, denying FitzPatrick’s appeal and remanding to the District Court for further consideration; reversing the District Court’s decision as to Minkow and remanding for further consideration; denying MacDonald’s appeal in its entirety; and denying Medifast’s appeal as to Coenen.  On September 26, 2014, the District Court obtained jurisdiction of the case once again and the parties set a briefing schedule on the outstanding issues remanded by the Ninth Circuit. Coenen filed a motion for attorneys’ fees, which Medifast has opposed. The Court issued an Order on the motion, granting it in part and denying it in part, on March 24, 2015. Judgment was entered on behalf of Coenen on April 21, 2015. Medifast has reached a settlement with Minkow and FitzPatrick.

Medifast entered into a number of Franchise Agreements with Team Wellness, Inc. and Team Wellness Louisiana, LLC for the operation of Medifast centers in the States of Alabama, Tennessee, and Louisiana. The primary owner and representative of the Team Wellness companies personally guaranteed the companies’ obligations. 

Team Wellness, Inc. failed  to make payments required under the terms of a Loan Agreement that Team Wellness, Inc. had entered into with Bank of America and for which Medifast provided a limited guarantee. As a result, Medifast served Team Wellness, Inc. with a Notice of Default and Opportunity to Cure. After Team Wellness, Inc. failed to cure and pay the outstanding amounts, Medifast served Team Wellness, Inc. with a Notice of Termination.  

When the companies and the primary guarantor failed to pay the monies owed or comply with their post-termination obligations, Medifast filed a lawsuit against the primary guarantor and the companies in the United States District Court for the District of Maryland. The complaint seeks damages, enforcement of the termination of the Franchise Agreements, and an injunction ordering the defendants to comply with their post-termination obligations under the Franchise Agreements. The matter is in its initial stages.

20

In addition to the above matters, the Company is, from time to time, subject to a variety of litigation and similar proceedings incidental to its business.   Based upon the Company’s experience, current information and applicable law, it does not believe that these proceedings and claims will have a material adverse effect on its results of operations, financial position or liquidity.

Item 1A. Risk Factors

There have been no material changes to the risk factors set forth in Part I, Item 1A of the Form 10-K.

Item 5. Other Information

At the outset of the quarter ended March 31, 2015, there were 1,211,908 shares of the Company’s common stock eligible for repurchase under the repurchase authorization dated September 16, 2014.

No repurchases were made during the first quarter of 2015.

21

Item 6. Exhibits

Exhibit Number	Description of Exhibit
3.1	Restated and Amended Certificate of Incorporation of the Company incorporated by reference to Exhibit 3.1 of the Company’s current report on Form 8-K filed February 27, 2015.
3.2	Amended and Restated Bylaws of Medifast, Inc. effective April 3, 2015 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-3573) filed on April 6, 2015).
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101	The following financial statements from Medifast, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2015 filed May 11, 2015, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Income, (iii) Condensed Consolidated Statements of Comprehensive Income, (iv) Condensed Consolidated Statements of Changes in Stockholders’ Equity (v) Condensed Consolidated Statements of Cash Flows, and (vi) Notes to the Unaudited Condensed Consolidated Financial Statements (filed herewith).

22

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

Medifast, Inc.

BY:	/S/ MICHAEL C. MACDONALD	May 11, 2015
	Michael C. MacDonald
	Chief Executive Officer
	(principal executive officer )

BY:	/S/ TIMOTHY G. ROBINSON	May 11, 2015
	Timothy G. Robinson
	Chief Financial Officer
	(principal financial officer)

23

EXHIBIT INDEX

Exhibit Number	Description of Exhibit
3.1	Restated and Amended Certificate of Incorporation of the Company incorporated by reference to Exhibit 3.1 of the Company’s current report on Form 8-K filed February 27, 2015.
3.2	Amended and Restated Bylaws of Medifast, Inc. effective April 3, 2015 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-3573) filed on April 6, 2016).
31.1*	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101*	The following financial statements from Medifast, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2015 filed May 11, 2015, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Income, (iii) Condensed Consolidated Statements of Comprehensive Income, (iv) Condensed Consolidated Statements of Changes in Stockholders’ Equity (v) Condensed Consolidated Statements of Cash Flows, and (vi) Notes to the Unaudited Condensed Consolidated Financial Statements (filed herewith).

* Exhibits filed herewith

In accordance with SEC Release No. 33-8238, Exhibit 32.1 is being furnished and not filed.

24

EX-31.1

Exhibit 31.1

RULE 13a-14(a) CERTIFICATION

I, Michael C. MacDonald, certify that:

1.	I have reviewed this report on Form 10-Q of Medifast, Inc.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 11, 2015

/s/	Michael C. MacDonald
	Michael C. MacDonald Chief Executive Officer

EX-31.2

Exhibit 31.2

RULE 13a-14(a) CERTIFICATION

I, Timothy G. Robinson, certify that:

1.	I have reviewed this report on Form 10-Q of Medifast, Inc.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 11, 2015

/s/	Timothy G. Robinson
	Timothy G. Robinson Chief Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q (the “Report”) for the quarter ended March 31, 2015 of Medifast, Inc. (the “Company”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael C. MacDonald, Chief Executive Officer and I, Timothy G. Robinson, Chief Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of the operations of the Company.

By:	/s/ Michael C. MacDonald
	Michael C. MacDonald
	Chief Executive Officer
	May 11, 2015
By:	/s/ Timothy G. Robinson
	Timothy G. Robinson
	Chief Financial Officer
	May 11, 2015

XML

Major Classes of Assets and Liabilities (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Receivables, net	$ 14,000
Inventory	0
Prepaid expenses and other current assets	4,000
Total current assets	18,000	184,000
Other assets	19,000
Total assets	37,000
Current liabilities:
Accounts payable and accrued expenses	2,348,000
Total current liabilities	2,348,000	4,858,000
Long-term lease obligations	1,712,000
Total liabilities	$ 4,060,000

XML

Schedule of Share Based Compensation Stock Options Activity (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, Outstanding Beginning Balance	67,375
Shares, Granted	53,500
Shares, Exercised	0
Shares, Forfeited	0
Shares, Expired	0
Shares, Outstanding Ending Balance	120,875
Shares, Exerciseable	36,281
Weighted-Average Exercise Price, Outstanding Beginning Balance	$ 26.05
Weighted-Average Exercise Price, Granted	$ 31.55
Weighted-Average Exercise Price, Exercised	$ 0
Weighted-Average Exercise Price, Forfeited	$ 0
Weighted-Average Exercise Price, Expired	$ 0
Weighted-Average Exercise Price, Oustanding Ending Balance	$ 28.49
Weighted-Average Exercise Price, Exerciseable	$ 26.29
Weighted-Average Remaining Contractual Life (Yrs), Outstanding	9 years 2 months 12 days
Weighted-Average Remaining Contractual Life (Yrs), Exerciseable	8 years 8 months 5 days
Aggregate Intrinsic Value, Outstanding	$ 264,084
Aggregate Intrinsic Value, Exerciseable	$ 137,633

XML

Business Segments (Tables)

3 Months Ended

Mar. 31, 2015

Segment Reporting, Disclosure Of Entity's Reportable Segments [Abstract]

Segment Information

The following table presents sales by channel for the three months ended March 31, 2015 and 2014:

	2015		2014
Medifast Direct	$	14,426,000	$	17,144,000
Take Shape For Life		52,102,000		56,966,000
Medifast Weight Control Centers- Franchise		4,681,000		3,588,000
Medifast Wholesale		2,155,000		1,535,000
Net Revenue	$	73,364,000	$	79,233,000

XML

Stockholders' Rights Plan - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2015
Stockholders Rights Plan [Line Items]
Investment Warrants Expiration Date	Aug. 28, 2015

XML

Contingencies - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2015
Loss Contingencies [Line Items]
Loss Contingency, Damages Sought, Value	$ 270
Financial Guarantee One [Member]
Loss Contingencies [Line Items]
Long-term Debt, Gross	1.0
Line of Credit Facility, Current Borrowing Capacity	1.0
Debt Instrument, Term	2 years
Debt Instrument, Payment Terms	payment calculations assume a 7 year amortization with a balloon payment due at the end of the term.
Line of Credit Facility, Description	line of credit has a two year term expiring in September 2015.
Line of Credit Facility, Expiration Date	Sep. 30, 2015
Financial Guarantee Two [Member]
Loss Contingencies [Line Items]
Long-term Debt, Gross	$ 1.4
Debt Instrument, Term	2 years
Debt Instrument, Payment Terms	payment calculations assume a 7 year amortization with a balloon payment due at the end of the term.

XML

Presentation of Financial Statements

3 Months Ended

Mar. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Presentation of Financial Statements

2. Presentation of Financial Statements

The Company’s condensed consolidated financial statements include the accounts of Medifast, Inc. and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.

XML

Earnings Per Share - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive options	79,925	59,542

XML

Earnings per Share (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Numerator:
Income from continuing operations	$ 4,416,000	$ 6,545,000
Income (loss) from discontinued operations	28,000	(578,000)
Net income	$ 4,444,000	$ 5,967,000
Denominator:
Weighted average shares of common stock outstanding	12,108,202	13,160,294
Effect of dilutive common stock equivalents	88,592	87,862
Weighted average shares of common stock outstanding	12,196,794	13,248,156
Basic earnings per share
Earnings per share from continuing operations	$ 0.36	$ 0.49
Earnings (loss) per share from discontinued operations	$ 0.00	$ (0.04)
Earnings per share	$ 0.36	$ 0.45
Diluted earnings per share
Earnings per share from continuing operations	$ 0.36	$ 0.49
Earnings (loss) per share from discontinued operations	$ 0.00	$ (0.04)
Earnings per share	$ 0.36	$ 0.45

XML

Available-For-Sale Securities Adjusted cost (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
Cash and Cash Equivalents and Marketable Securities [Line Items]
Cost	$ 60,440,000	$ 51,833,000
Unrealized Gains	1,039,000	914,000
Unrealized Losses	(162,000)	(184,000)
Accrued Interest	61,000	81,000
Estimated Fair Value	61,378,000	52,644,000
Cash & Cash Equivalents	33,423,000	24,459,000	41,360,000	36,382,000
Investment Securities	27,955,000	28,185,000
Cash
Cash and Cash Equivalents and Marketable Securities [Line Items]
Cost	32,242,000	23,894,000
Unrealized Gains	0	0
Unrealized Losses	0	0
Accrued Interest	0	0
Estimated Fair Value	32,242,000	23,894,000
Cash & Cash Equivalents	32,242,000	23,894,000
Investment Securities	0	0
Fair Value, Inputs, Level 1
Cash and Cash Equivalents and Marketable Securities [Line Items]
Cost	19,870,000	19,265,000
Unrealized Gains	901,000	807,000
Unrealized Losses	(151,000)	(165,000)
Accrued Interest	10,000	15,000
Estimated Fair Value	20,630,000	19,922,000
Cash & Cash Equivalents	1,181,000	565,000
Investment Securities	19,449,000	19,357,000
Fair Value, Inputs, Level 1 | Money Market Accounts
Cash and Cash Equivalents and Marketable Securities [Line Items]
Cost	1,181,000	565,000
Unrealized Gains	0	0
Unrealized Losses	0	0
Accrued Interest	0	0
Estimated Fair Value	1,181,000	565,000
Cash & Cash Equivalents	1,181,000	565,000
Investment Securities	0	0
Fair Value, Inputs, Level 1 | Mutual Funds
Cash and Cash Equivalents and Marketable Securities [Line Items]
Cost	10,508,000	10,733,000
Unrealized Gains	124,000	63,000
Unrealized Losses	(99,000)	(129,000)
Accrued Interest	0	0
Estimated Fair Value	10,533,000	10,667,000
Cash & Cash Equivalents	0	0
Investment Securities	10,533,000	10,667,000
Fair Value, Inputs, Level 1 | Corporate Equity Securities
Cash and Cash Equivalents and Marketable Securities [Line Items]
Cost	3,785,000	3,408,000
Unrealized Gains	709,000	695,000
Unrealized Losses	(51,000)	(31,000)
Accrued Interest	0	0
Estimated Fair Value	4,443,000	4,072,000
Cash & Cash Equivalents	0	0
Investment Securities	4,443,000	4,072,000
Fair Value, Inputs, Level 1 | Government Agency Securities
Cash and Cash Equivalents and Marketable Securities [Line Items]
Cost	4,396,000	4,559,000
Unrealized Gains	68,000	49,000
Unrealized Losses	(1,000)	(5,000)
Accrued Interest	10,000	15,000
Estimated Fair Value	4,473,000	4,618,000
Cash & Cash Equivalents	0	0
Investment Securities	4,473,000	4,618,000
Fair Value, Inputs, Level 2
Cash and Cash Equivalents and Marketable Securities [Line Items]
Cost	8,328,000	8,674,000
Unrealized Gains	138,000	107,000
Unrealized Losses	(11,000)	(19,000)
Accrued Interest	51,000	66,000
Estimated Fair Value	8,506,000	8,828,000
Cash & Cash Equivalents	0	0
Investment Securities	8,506,000	8,828,000
Fair Value, Inputs, Level 2 | Municipal Bonds
Cash and Cash Equivalents and Marketable Securities [Line Items]
Cost	3,448,000	3,652,000
Unrealized Gains	73,000	78,000
Unrealized Losses	(7,000)	(7,000)
Accrued Interest	21,000	28,000
Estimated Fair Value	3,535,000	3,751,000
Cash & Cash Equivalents	0	0
Investment Securities	3,535,000	3,751,000
Fair Value, Inputs, Level 2 | Corporate Bonds
Cash and Cash Equivalents and Marketable Securities [Line Items]
Cost	4,880,000	5,022,000
Unrealized Gains	65,000	29,000
Unrealized Losses	(4,000)	(12,000)
Accrued Interest	30,000	38,000
Estimated Fair Value	4,971,000	5,077,000
Cash & Cash Equivalents	0	0
Investment Securities	$ 4,971,000	$ 5,077,000

XML

Financial Instruments - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Financial Instruments [Line Items]
Realized Gain (Loss) on Marketable Securities, Cost Method Investments, and Other Investments	$ 118,000	$ 188,000

XML

Basis of Presentation

3 Months Ended

Mar. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

1. Basis of Presentation

The condensed unaudited interim consolidated financial statements included herein have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”), without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). However, in the opinion of management, all adjustments consisting of normal, recurring adjustments considered necessary for a fair presentation of the financial position and results of operations have been included. The condensed consolidated financial statements and notes are presented as permitted on Form 10-Q. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading.

The results of operations for the three months ended March 31, 2015 are not necessarily indicative of results that may be expected for the year ending December 31, 2015. The accompanying condensed unaudited interim consolidated financial statements should be read in conjunction with the 2014 audited financial statements and notes thereto, which are included in the Company’s Annual Report on Form 10-K, as amended, filed with the SEC for the year ended December 31, 2014 (“2014 Form 10-K”).

XML

Schedule of Assumptions Used (Detail)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life (in years)	6 years	6 years
Risk-free interest rate	1.72%	1.61%
Expected volatility	52.69%	63.15%
Dividend yield	0.00%	0.00%

XML

Summary of Accrued (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015		Dec. 31, 2014
Summary Of Expenses [Line Items]
Charges incurred during the period	$ 0
Adjustments recorded during the period	(549,000)	[1]
Payments during the period	(2,042,000)
Accrued Balance	$ 3,943,000		$ 6,534,000

[1] The adjustments to the accrual recorded in the first quarter of 2015 relate primarily to favorable termination agreements reached with landlords of closed Corporate Medifast Weight Control Centers.

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 33,423,000	$ 24,459,000
Accounts receivable-net of allowance for sales returns and doubtful accounts of $397,000 and $354,000	2,306,000	1,650,000
Inventory	14,186,000	15,735,000
Investment securities	27,955,000	28,185,000
Income taxes, prepaid	3,897,000	5,099,000
Prepaid expenses and other current assets	2,814,000	2,875,000
Deferred tax assets	2,978,000	3,727,000
Current assets of discontinued operations	18,000	184,000
Total current assets	87,577,000	81,914,000
Property, plant and equipment - net	32,507,000	33,477,000
Other assets	162,000	497,000
Long-term assets of discontinued operations	19,000	22,000
TOTAL ASSETS	120,265,000	115,910,000
Current liabilities:
Accounts payable and accrued expenses	25,468,000	21,854,000
Current maturities of capital leases	234,000	232,000
Current liabilities of discontinued operations	2,348,000	4,858,000
Total current liabilities	28,050,000	26,944,000
Other liabilities:
Capital leases, net of current portion	183,000	242,000
Deferred tax liabilities	5,493,000	5,492,000
Long-term liabilities of discontinued operations	1,712,000	2,756,000
Total liabilities	35,438,000	35,434,000
Stockholders' Equity:
Common stock; par value $.001 per share; 20,000,000 shares authorized; 12,391,652 and 12,365,690 issued 12,124,699 and 12,075,764 issued and outstanding	12,000	12,000
Additional paid-in capital	951,000	1,132,000
Accumulated other comprehensive income	523,000	435,000
Retained earnings	83,341,000	78,897,000
Total stockholders' equity	84,827,000	80,476,000
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 120,265,000	$ 115,910,000

XML

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock	Additional Paid- In Capital	Retained Earnings	Accumulated other comprehensive income
Balance at Dec. 31, 2014	$ 80,476,000	$ 12,000	$ 1,132,000	$ 78,897,000	$ 435,000
Balance (in shares) at Dec. 31, 2014		12,365,690
Shares issued to executives and directors (in shares)		25,962
Share-based compensation	529,000		529,000
Net shares repurchased for employee taxes	(875,000)		(875,000)
Share-based compensation tax benefit	165,000		165,000
Net income	4,444,000			4,444,000
Net change in unrealized gain on investments	88,000				88,000
Balance at Mar. 31, 2015	$ 84,827,000	$ 12,000	$ 951,000	$ 83,341,000	$ 523,000
Balance (in shares) at Mar. 31, 2015		12,391,652

XML

Shared-based Compensation - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to restricted stock awards	$ 1,300,000
Compensation cost recognition weighted average period	2 years 6 months
Share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value	$ 16.00
Sharebased compensation arrangement by sharebased payment award options expiration term	10 years
Sharebased compensation arrangement by sharebased payment award options vesting period	3 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, shares authorized under stock option plans, exercise price range, upper range limit	$ 31.55
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, shares authorized under stock option plans, exercise price range, lower range limit	$ 24.26
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards vested and charged	530,000	774,000
Total income tax benefit recognized related to restricted stock awards	210,000	243,000
Unrecognized compensation cost related to restricted stock awards	5,400,000
Compensation cost recognition weighted average period	2 years 8 months 12 days
Share based compensation expense	349,000	338,000
Award vesting period	5 years
Total Tax Benefit Recognized In Additional Paid-in Capital Upon Vesting Of Restricted Stock Awards	$ 165,000	$ 0

XML

Earnings per Share (Tables)

3 Months Ended

Mar. 31, 2015

Earnings Per Share [Abstract]

Earnings Per Share, Basic and Diluted

The following table sets forth the computation of basic and diluted EPS for the three months ended March 31:

	Three Months Ended March 31,
	2015		2014
Numerator:
Income from continuing operations	$	4,416,000	$	6,545,000
Income (loss) from discontinued operations		28,000		(578,000)
Net income	$	4,444,000	$	5,967,000
Denominator:
Weighted average shares of common stock outstanding		12,108,202		13,160,294
Effect of dilutive common stock equivalents		88,592		87,862
Weighted average shares of common stock outstanding		12,196,794		13,248,156
EPS:
Basic earnings per share
Earnings per share from continuing operations	$	0.36	$	0.49
Earnings (loss) per share from discontinued operations	$	0.00	$	(0.04)
Earnings per share	$	0.36	$	0.45
Diluted earnings per share
Earnings per share from continuing operations	$	0.36	$	0.49
Earnings (loss) per share from discontinued operations	$	0.00	$	(0.04)
Earnings per share	$	0.36	$	0.45

XML

Sales by Channel (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Segment Reporting Information [Line Items]
Net Revenue	$ 73,364,000	$ 79,233,000
Medifast Direct
Segment Reporting Information [Line Items]
Net Revenue	14,426,000	17,144,000
Take Shape For Life
Segment Reporting Information [Line Items]
Net Revenue	52,102,000	56,966,000
Medifast Weight Control Centers- Franchise
Segment Reporting Information [Line Items]
Net Revenue	4,681,000	3,588,000
Medifast Wholesale
Segment Reporting Information [Line Items]
Net Revenue	$ 2,155,000	$ 1,535,000

XML

Shared-based Compensation (Tables)

3 Months Ended

Mar. 31, 2015

Share-Based Compensation [Abstract]

Schedule of Assumptions Used

The weighted average input assumptions used and resulting fair values were as follows:

	2015			2014
Expected life (in years)		6			6
Risk-free interest rate		1.72	%		1.61	%
Expected volatility		52.69	%		63.15	%
Dividend yield		-			-

Schedule of Share-based Compensation, Stock Options, Activity

The following table summarizes the stock option activity:

	Shares		Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Life (Yrs)		Aggregate Intrinsic Value
Outstanding at December 31, 2014		67,375	$	26.05
Granted		53,500		31.55
Exercised		-		-
Forfeited		-		-
Expired		-		-
Outstanding at March 31, 2015		120,875	$	28.49		9.20		264,084
Exerciseable at March 31, 2015		36,281	$	26.29		8.68		137,633

Restricted Stock Activity

The following table summarizes the restricted stock activity:

	Shares		Weighted-Average Grant Date Fair Value
Unvested at December 31, 2014		333,676	$	25.31
Granted		8,980		31.55
Vested		(75,703)		25.08
Forfeited		-		-
Unvested at March 31, 2015		266,953	$	25.59

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net income	$ 4,444,000	$ 5,967,000
Income (loss) from discontinued operations, net of tax	28,000	(578,000)
Income from continuing operations	4,416,000	6,545,000
Adjustments to reconcile net income to net cash provided by operating activities from continuing operations:
Depreciation and amortization	1,877,000	2,029,000
Realized (gain) loss on investment securities, net	(118,000)	(188,000)
Share-based compensation	529,000	774,000
Deferred income taxes	(154,000)	(381,000)
(Gain) on disposal of fixed assets	0	(32,000)
Changes in assets and liabilities which provided (used) cash:
Accounts receivable	(656,000)	(204,000)
Inventory	1,549,000	2,120,000
Prepaid expenses and other current assets	16,000	(67,000)
Other assets	335,000	2,000
Accounts payable and accrued expenses	3,615,000	(82,000)
Income taxes	1,202,000	610,000
Net cash provided by operating activities- continuing operations	12,611,000	11,126,000
Net cash used in operating activities- discontinued operations	(2,513,000)	(505,000)
Net cash provided by operating activities	10,098,000	10,621,000
Cash Flow from Investing Activities:
Sale of investment securities	2,022,000	3,572,000
Purchase of investment securities	(1,526,000)	(7,943,000)
Purchase of property and equipment	(907,000)	(1,182,000)
Net cash used in investing activities- continuing operations	(411,000)	(5,553,000)
Net cash used in investing activities- discontinued operations	0	(42,000)
Net cash used in investing activities	(411,000)	(5,595,000)
Cash Flow from Financing Activities:
Repayment of long-term debt and capital leases	(57,000)	(55,000)
Decrease in note receivable	45,000	7,000
Net shares repurchased for employee taxes	(875,000)	0
Excess tax benefits from share-based compensation	165,000	0
Net cash used in financing activities- continuing operations	(722,000)	(48,000)
Net cash used in financing activities- discontinued operations	0	0
Net cash used in financing activities	(722,000)	(48,000)
NET CHANGE IN CASH AND CASH EQUIVALENTS	8,965,000	4,978,000
Cash and cash equivalents - beginning of the period	24,459,000	36,382,000
Cash and cash equivalents - end of period	33,423,000	41,360,000
Supplemental disclosure of cash flow information:
Interest paid	10,000	53,000
Income taxes paid	$ 295,000	$ 2,687,000

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Accounts receivable, allowance for sales returns and doubtful accounts	$ 397,000	$ 354,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	20,000,000	20,000,000
Common stock, issued	12,391,652	12,365,690
Common stock, outstanding	12,124,699	12,075,764

XML

Business Segments

3 Months Ended

Mar. 31, 2015

Segment Reporting, Disclosure Of Entity's Reportable Segments [Abstract]

Business Segments

10. Business Segments

Operating segments are components of an enterprise about which separate financial information is available that is regularly reviewed by the chief operating decision maker about how to allocate resources and in assessing performance. The consolidated operating profit of the Company is reviewed by the chief operating decision maker as a single segment and sales are reviewed at the channel level.

The following table presents sales by channel for the three months ended March 31, 2015 and 2014:

	2015		2014
Medifast Direct	$	14,426,000	$	17,144,000
Take Shape For Life		52,102,000		56,966,000
Medifast Weight Control Centers- Franchise		4,681,000		3,588,000
Medifast Wholesale		2,155,000		1,535,000
Net Revenue	$	73,364,000	$	79,233,000

XML

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	May 11, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Entity Registrant Name	MEDIFAST INC
Entity Central Index Key	0000910329
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	MED
Entity Common Stock, Shares Outstanding		12,124,699

XML

Contingencies

3 Months Ended

Mar. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Contingencies

11. Contingencies

The Company filed a civil complaint on February 17, 2010 in the U.S. District Court (SD, Cal) against Barry Minkow and the Fraud Discovery Institute, Inc. (collectively, “Minkow”), iBusiness Reporting, and its editor William Lobdell, Tracy Coenen and Sequence, Inc. (collectively, “Coenen”), “Zee Yourself”, and Robert L. Fitzpatrick (“FitzPatrick”) for defamation, market manipulation and unfair business practices, alleging a scheme of market manipulation of Medifast stock for Defendants’ for monetary gain, and damaging the business reputation of Medifast and its Take Shape For Life division. Bradley T. MacDonald, former Executive Chairman of Medifast and a stockholder, joined the lawsuit individually.  The lawsuit seeks $270 million in compensatory damages, punitive damages, and ancillary relief.  In March 2011, the District Court granted in part and denied in part certain Anti-SLAPP Motions to Strike (i.e. motions to dismiss) previously filed by all Defendants.  The Company appealed that portion of the District Court’s ruling which dismissed its defamation claims against Minkow and Coenen in the 9th Circuit Court of Appeals.  Defendant FitzPatrick’s motion was denied as to the Company’s defamation claim, and FitzPatrick appealed that portion of the Court’s ruling.  On June 4, 2014, the Panel of the 9th Circuit Court of Appeals issued a decision, denying FitzPatrick’s appeal and remanding to the District Court for further consideration; reversing the District Court’s decision as to Minkow and remanding for further consideration; denying MacDonald’s appeal in its entirety; and denying Medifast’s appeal as to Coenen.  On September 26, 2014, the District Court obtained jurisdiction of the case once again and the parties set a briefing schedule on the outstanding issues remanded by the Ninth Circuit. Coenen filed a motion for attorneys’ fees, which Medifast has opposed. The Court issued an Order on the motion, granting it in part and denying it in part, on March 24, 2015. Judgment was entered on behalf of Coenen on April 21, 2015.

The Company entered into guarantee agreements with two key franchisee partners in order to support them obtaining additional funding to expand their business into new markets. This is in line with the Company’s long-term strategy of expanding the franchise business utilizing knowledgeable franchise partners. The loans associated with these agreements have been paid in full. The first guarantee provides financial coverage for a $1.0 million loan and a $1.0 million line of credit. The variable rate term loan has a 2 year term expiring in September 2015; payment calculations assume a 7 year amortization with a balloon payment due at the end of the term. The line of credit has a two year term expiring in September 2015. The franchisee associated with these loans failed to pay the monthly obligations and the Company paid off the loans in April 2015. The Company is a secondary guarantor on the loan and line of credit and has pursued personal recourse against the franchise owner. The second guarantee provides financial coverage for a $1.4 million loan and was paid in full in March 2015. The variable rate term loan has a 2 year term expiring in October 2015; payment calculations assume a 7 year amortization with a balloon payment due at the end of the term. The Company is the third guarantor on these loans and has recourse against another entity owned by the franchisee and the franchisee owner(s) themselves should it be deemed necessary.

XML

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenue	$ 73,364,000	$ 79,233,000
Cost of sales	19,594,000	21,309,000
Gross Profit	53,770,000	57,924,000
Selling, general, and administrative	47,258,000	48,313,000
Income from operations	6,512,000	9,611,000
Other income
Interest and dividend income, net	132,000	135,000
Other income	148,000	184,000
Nonoperating Income (Expense)	280,000	319,000
Income from continuing operations before income taxes	6,792,000	9,930,000
Provision for income taxes	2,376,000	3,385,000
Income from continuing operations	4,416,000	6,545,000
Income (loss) from discontinued operations, net of tax	28,000	(578,000)
Net income	$ 4,444,000	$ 5,967,000
Basic earnings per share
Earnings per share from continuing operations	$ 0.36	$ 0.49
Earnings (Loss) per share from discontinued operations	$ 0.00	$ (0.04)
Earnings per share	$ 0.36	$ 0.45
Diluted earnings per share
Earnings per share from continuing operations	$ 0.36	$ 0.49
Earnings (Loss) per share from discontinued operations	$ 0.00	$ (0.04)
Earnings per share	$ 0.36	$ 0.45
Weighted average shares outstanding -
Basic	12,108,202	13,160,294
Diluted	12,196,794	13,248,156

XML

Inventories

3 Months Ended

Mar. 31, 2015

Inventory Disclosure [Abstract]

Inventories

5. Inventories

Inventories consist principally of packaged meal replacements held in the Company’s warehouses. Inventory is stated at the lower of cost or market, utilizing the first-in, first-out method. The cost of finished goods includes the cost of raw materials, packaging supplies, direct and indirect labor and other indirect manufacturing costs. On a quarterly basis, management reviews inventory for unsalable or obsolete inventory.

Inventories consisted of the following at March 31, 2015 and December 31, 2014:

	2015		2014
Raw Materials	$	3,692,000	$	4,410,000
Packaging		1,105,000		920,000
Non-food Finished Goods		879,000		1,108,000
Finished Goods		8,817,000		9,689,000
Reserve for Obsolete Inventory		(307,000)		(392,000)
	$	14,186,000	$	15,735,000

XML

Revenue Recognition

3 Months Ended

Mar. 31, 2015

Revenue Recognition [Abstract]

Revenue Recognition

4. Revenue Recognition

Revenue is recognized net of discounts, rebates, promotional adjustments, price adjustments, and estimated returns and upon transfer of title and risk to the customer which primarily occurs at shipping (F.O.B. terms). Upon shipment, the Company has no further performance obligations and collection is reasonably assured as the majority of sales are paid for prior to shipping.

XML

Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2015

Investments, All Other Investments [Abstract]

Cash and Available For Sale Securities Adjusted Cost Gross Unrealized Gains Gross Unrealized Losses and Fair Value By Significant Investment Category

The following table represents cash and the available-for-sale securities adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category recorded as cash and cash equivalents or investment securities as of March 31, 2015 and December 31, 2014:

	March 31, 2015
	Cost		Unrealized Gains		Unrealized Losses		Accrued Interest		Estimated Fair Value		Cash & Cash Equivalents		Investment Securities
Cash	$	32,242,000	$	-	$	-	$	-	$	32,242,000	$	32,242,000	$	-
Level 1:
Money Market Accounts		1,181,000		-		-		-		1,181,000		1,181,000		-
Mutual Funds		10,508,000		124,000		(99,000)		-		10,533,000		-		10,533,000
Corporate Equity Securities		3,785,000		709,000		(51,000)		-		4,443,000		-		4,443,000
Government & Agency Securities		4,396,000		68,000		(1,000)		10,000		4,473,000		-		4,473,000
		19,870,000		901,000		(151,000)		10,000		20,630,000		1,181,000		19,449,000
Level 2:
Municipal Bonds		3,448,000		73,000		(7,000)		21,000		3,535,000		-		3,535,000
Corporate Bonds		4,880,000		65,000		(4,000)		30,000		4,971,000		-		4,971,000
		8,328,000		138,000		(11,000)		51,000		8,506,000		-		8,506,000
Total	$	60,440,000	$	1,039,000	$	(162,000)	$	61,000	$	61,378,000	$	33,423,000	$	27,955,000

	December 31, 2014
	Cost		Unrealized Gains		Unrealized Losses		Accrued Interest		Estimated Fair Value		Cash & Cash Equivalents		Investment Securities
Cash	$	23,894,000	$	-	$	-	$	-	$	23,894,000	$	23,894,000	$	-
Level 1:
Money Market Accounts		565,000		-		-		-		565,000		565,000		-
Mutual Funds		10,733,000		63,000		(129,000)		-		10,667,000		-		10,667,000
Corporate Equity Securities		3,408,000		695,000		(31,000)		-		4,072,000		-		4,072,000
Government & Agency Securities		4,559,000		49,000		(5,000)		15,000		4,618,000		-		4,618,000
		19,265,000		807,000		(165,000)		15,000		19,922,000		565,000		19,357,000
Level 2:
Municipal Bonds		3,652,000		78,000		(7,000)		28,000		3,751,000		-		3,751,000
Corporate Bonds		5,022,000		29,000		(12,000)		38,000		5,077,000		-		5,077,000
		8,674,000		107,000		(19,000)		66,000		8,828,000		-		8,828,000
Total	$	51,833,000	$	914,000	$	(184,000)	$	81,000	$	52,644,000	$	24,459,000	$	28,185,000

XML

Discontinued Operations, Exit Activities, and Clinic Obligations

3 Months Ended

Mar. 31, 2015

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations, Exit Activities, and Clinic Obligations

12. Discontinued Operations, Exit Activities, and Clinic Obligations

In 2014, the Company exited the MWCC corporate center model by selling 41 centers to existing franchise partners (24 centers were sold in June 2014 and the remaining 17 centers were sold in December 2014) and closing the remaining 34 corporate centers. In accordance with ASU 2014-08, Presentation of Financial Statements (Topic 205) and Property Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity the assets, liabilities, operating results, and cash flows of the MWCC corporate center channel have been presented separately as discontinued operations in the Consolidated Financial Statements for all periods presented.

The following is a summary of the Company’s operating results for discontinued operations for the three months ended March 31, 2015 and 2014:

	2015		2014
Revenue	$	-	$	7,296,000
Income/(loss) before income taxes from discontinued operations		45,000		(924,000)
Income tax/(benefit) provision		17,000		(346,000)
Income/(loss) from discontinued operations, net of tax	$	28,000	$	(578,000)

The following table presents the aggregate carrying amounts of the major classes of assets and liabilities divested as of March 31, 2015 included in discontinued operations:

	2015
ASSETS
Current assets:
Receivables, net	$	14,000
Inventory		-
Prepaid expenses and other current assets		4,000
Total current assets		18,000
Other assets		19,000
Total assets	$	37,000
LIABILITIES
Current liabilities:
Accounts payable and accrued expenses	$	2,348,000
Total current liabilities		2,348,000
Long-term lease obligations		1,712,000
Total liabilities	$	4,060,000

The following table summarizes the exit obligations primarily closed clinic lease obligations, severance accruals, and customer refunds incurred as of March 31, 2015:

Ending accrued balance as of December 31, 2014	$	6,534,000
Charges incurred during the period		-
Adjustments recorded during the period (1)		(549,000)
Payments during the period		(2,042,000)
Ending accrued balance as of March 31, 2015	$	3,943,000
(1)- The adjustments to the accrual recorded in the first quarter of 2015 relate primarily to favorable termination agreements reached with landlords of closed Corporate Medifast Weight Control Centers.
These charges were recorded in the balance sheet as of March 31, 2015 as follows:
Total current liabilities of discontinued operations	$	2,231,000
Total long-term liabilities of discontinued operations		1,712,000
Ending accrued balance as of December 31, 2014	$	3,943,000

XML

Financial Instruments

3 Months Ended

Mar. 31, 2015

Investments, All Other Investments [Abstract]

Financial Instruments

8. Financial Instruments

Certain financial assets and liabilities are accounted for at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The following fair value hierarchy prioritizes the inputs used to measure fair value:

Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2 – Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies.

Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value from the perspective of a market participant.

The following table represents cash and the available-for-sale securities adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category recorded as cash and cash equivalents or investment securities as of March 31, 2015 and December 31, 2014:

	March 31, 2015
	Cost		Unrealized Gains		Unrealized Losses		Accrued Interest		Estimated Fair Value		Cash & Cash Equivalents		Investment Securities
Cash	$	32,242,000	$	-	$	-	$	-	$	32,242,000	$	32,242,000	$	-
Level 1:
Money Market Accounts		1,181,000		-		-		-		1,181,000		1,181,000		-
Mutual Funds		10,508,000		124,000		(99,000)		-		10,533,000		-		10,533,000
Corporate Equity Securities		3,785,000		709,000		(51,000)		-		4,443,000		-		4,443,000
Government & Agency Securities		4,396,000		68,000		(1,000)		10,000		4,473,000		-		4,473,000
		19,870,000		901,000		(151,000)		10,000		20,630,000		1,181,000		19,449,000
Level 2:
Municipal Bonds		3,448,000		73,000		(7,000)		21,000		3,535,000		-		3,535,000
Corporate Bonds		4,880,000		65,000		(4,000)		30,000		4,971,000		-		4,971,000
		8,328,000		138,000		(11,000)		51,000		8,506,000		-		8,506,000
Total	$	60,440,000	$	1,039,000	$	(162,000)	$	61,000	$	61,378,000	$	33,423,000	$	27,955,000

	December 31, 2014
	Cost		Unrealized Gains		Unrealized Losses		Accrued Interest		Estimated Fair Value		Cash & Cash Equivalents		Investment Securities
Cash	$	23,894,000	$	-	$	-	$	-	$	23,894,000	$	23,894,000	$	-
Level 1:
Money Market Accounts		565,000		-		-		-		565,000		565,000		-
Mutual Funds		10,733,000		63,000		(129,000)		-		10,667,000		-		10,667,000
Corporate Equity Securities		3,408,000		695,000		(31,000)		-		4,072,000		-		4,072,000
Government & Agency Securities		4,559,000		49,000		(5,000)		15,000		4,618,000		-		4,618,000
		19,265,000		807,000		(165,000)		15,000		19,922,000		565,000		19,357,000
Level 2:
Municipal Bonds		3,652,000		78,000		(7,000)		28,000		3,751,000		-		3,751,000
Corporate Bonds		5,022,000		29,000		(12,000)		38,000		5,077,000		-		5,077,000
		8,674,000		107,000		(19,000)		66,000		8,828,000		-		8,828,000
Total	$	51,833,000	$	914,000	$	(184,000)	$	81,000	$	52,644,000	$	24,459,000	$	28,185,000

The Company had realized gains of $118,000 and $188,000 for the three months ended March 31, 2015 and 2014, respectively.

XML

Earnings per Share

3 Months Ended

Mar. 31, 2015

Earnings Per Share [Abstract]

Earnings Per Share

6. Earnings per Share

Basic earnings per share (“EPS”) computations are calculated utilizing the weighted average number of shares of common stock outstanding during the periods presented. Diluted EPS is calculated utilizing the weighted average number of shares of common stock outstanding adjusted for the effect of dilutive common stock equivalents.

The following table sets forth the computation of basic and diluted EPS for the three months ended March 31:

	Three Months Ended March 31,
	2015		2014
Numerator:
Income from continuing operations	$	4,416,000	$	6,545,000
Income (loss) from discontinued operations		28,000		(578,000)
Net income	$	4,444,000	$	5,967,000
Denominator:
Weighted average shares of common stock outstanding		12,108,202		13,160,294
Effect of dilutive common stock equivalents		88,592		87,862
Weighted average shares of common stock outstanding		12,196,794		13,248,156
EPS:
Basic earnings per share
Earnings per share from continuing operations	$	0.36	$	0.49
Earnings (loss) per share from discontinued operations	$	0.00	$	(0.04)
Earnings per share	$	0.36	$	0.45
Diluted earnings per share
Earnings per share from continuing operations	$	0.36	$	0.49
Earnings (loss) per share from discontinued operations	$	0.00	$	(0.04)
Earnings per share	$	0.36	$	0.45

The calculation of diluted earnings per share excluded 79,925 and 59,542 options outstanding for the three months ended March 31, 2015 and 2014, respectively, that could potentially dilute base earnings per share in the future.

XML

Estimates

3 Months Ended

Mar. 31, 2015

Estimates [Abstract]

Estimates

7. Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

XML

Shared-based Compensation

3 Months Ended

Mar. 31, 2015

Share-Based Compensation [Abstract]

Shared-based Compensation

9. Shared-based Compensation

Stock Options:

The Company has issued non-qualified and incentive stock options to employees and nonemployee directors. The fair value of these options are estimated on the date of grant using the Black-Scholes option pricing model, which requires estimates of the expected term of the option, the expected volatility of the price of the Company’s common stock, dividend yield and the risk-free interest rate. Options outstanding as of March 31, 2015 vest over a period of three years with an expiration term of ten years. The exercise price of these options ranges from $24.26 to $31.55. The expected volatility is based on the historical volatility of the Company’s common stock over the period of time equivalent to the expected term for each award. Due to the Company’s lack of option exercise history, the expected term is calculated using the simplified method defined as the midpoint between the vesting period and the contractual term of each award. The risk free interest rate is based on the U.S. Treasury yield curve in effect on the date of grant which most closely corresponds to the expected term of the option. The Company historically has not issued dividends and therefore does not utilize a dividend yield in the calculation. The weighted average input assumptions used and resulting fair values were as follows:

	2015			2014
Expected life (in years)		6			6
Risk-free interest rate		1.72	%		1.61	%
Expected volatility		52.69	%		63.15	%
Dividend yield		-			-

The following table summarizes the stock option activity:

	Shares		Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Life (Yrs)		Aggregate Intrinsic Value
Outstanding at December 31, 2014		67,375	$	26.05
Granted		53,500		31.55
Exercised		-		-
Forfeited		-		-
Expired		-		-
Outstanding at March 31, 2015		120,875	$	28.49		9.20		264,084
Exerciseable at March 31, 2015		36,281	$	26.29		8.68		137,633

The weighted-average grant date fair value of options granted was $16.00. The unrecognized compensation expense calculated under the fair value method for shares expected to vest as of March 31, 2015 was approximately $1.3 million and is expected to be recognized over a weighted average period of 2.5 years.

Restricted Stock:

The Company has issued restricted stock to employees and nonemployee directors generally with terms up to five years. The fair value is equal to the market price of the Company’s common stock on the date of grant. Expense for restricted stock is amortized ratably over the vesting period. The following table summarizes the restricted stock activity:

	Shares		Weighted-Average Grant Date Fair Value
Unvested at December 31, 2014		333,676	$	25.31
Granted		8,980		31.55
Vested		(75,703)		25.08
Forfeited		-		-
Unvested at March 31, 2015		266,953	$	25.59

The total costs of the options and restricted awards vested and charged against income during the three months ended March 31, 2015 and 2014 was $530,000 and $774,000, respectively. The Company accrued an additional $349,000 and $338,000 for performance awards for the three months ended March 31, 2015 and 2014, respectively. The cost of the 2015 awards will depend on the Company’s fiscal 2015 performance and will be finalized and approved at the first Board of Directors meeting in 2016. The cost recognized during the quarter is based on the performance that management expects the Company will achieve as of March 31, 2015. The total income tax benefit recognized in the consolidated statements of income for these restricted stock awards was approximately $210,000 and $243,000 for the three months ended March 31, 2015 and 2014, respectively. The total tax benefit recognized in additional paid-in capital upon vesting of restricted stock awards for the three months ended March 31, 2015 was $165,000. No tax benefit was recognized in additional paid-in capital upon vesting of the restricted stock awards in the three months ended March, 31 2014. There was approximately $5.4 million of total unrecognized compensation cost related to restricted stock awards as of March 31, 2015. The cost is expected to be recognized over a weighted-average period of approximately 2.7 years.

XML

Summary of Restricted Stock Activity (Detail) (Restricted Stock, USD $)	3 Months Ended
	Mar. 31, 2015
Restricted Stock
Shares
Unvested at December 31, 2014	333,676
Granted	8,980
Vested	(75,703)
Forfeited	0
Unvested at March 31,2015	266,953
Weighted-Average Grant Date Fair Value
Unvested at December 31, 2014	$ 25.31
Granted	$ 31.55
Vested	$ 25.08
Forfeited	$ 0
Unvested at March 31, 2015	$ 25.59

XML

Inventories (Tables)

3 Months Ended

Mar. 31, 2015

Inventory Disclosure [Abstract]

Inventories

Inventories consisted of the following at March 31, 2015 and December 31, 2014:

	2015		2014
Raw Materials	$	3,692,000	$	4,410,000
Packaging		1,105,000		920,000
Non-food Finished Goods		879,000		1,108,000
Finished Goods		8,817,000		9,689,000
Reserve for Obsolete Inventory		(307,000)		(392,000)
	$	14,186,000	$	15,735,000

XML

Discontinued Operations, Exit Activities, and Clinic Obligations (Tables)

3 Months Ended

Mar. 31, 2015

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures

The following is a summary of the Company’s operating results for discontinued operations for the three months ended March 31, 2015 and 2014:

	2015		2014
Revenue	$	-	$	7,296,000
Income/(loss) before income taxes from discontinued operations		45,000		(924,000)
Income tax/(benefit) provision		17,000		(346,000)
Income/(loss) from discontinued operations, net of tax	$	28,000	$	(578,000)

The following table presents the aggregate carrying amounts of the major classes of assets and liabilities divested as of March 31, 2015 included in discontinued operations:

	2015
ASSETS
Current assets:
Receivables, net	$	14,000
Inventory		-
Prepaid expenses and other current assets		4,000
Total current assets		18,000
Other assets		19,000
Total assets	$	37,000
LIABILITIES
Current liabilities:
Accounts payable and accrued expenses	$	2,348,000
Total current liabilities		2,348,000
Long-term lease obligations		1,712,000
Total liabilities	$	4,060,000

Schedule of Accrued Liabilities

The following table summarizes the exit obligations primarily closed clinic lease obligations, severance accruals, and customer refunds incurred as of March 31, 2015:

Ending accrued balance as of December 31, 2014	$	6,534,000
Charges incurred during the period		-
Adjustments recorded during the period (1)		(549,000)
Payments during the period		(2,042,000)
Ending accrued balance as of March 31, 2015	$	3,943,000
(1)- The adjustments to the accrual recorded in the first quarter of 2015 relate primarily to favorable termination agreements reached with landlords of closed Corporate Medifast Weight Control Centers.
These charges were recorded in the balance sheet as of March 31, 2015 as follows:
Total current liabilities of discontinued operations	$	2,231,000
Total long-term liabilities of discontinued operations		1,712,000
Ending accrued balance as of December 31, 2014	$	3,943,000

XML

Discontinued Operations Accrued Balance (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total current liabilities of discontinued operations	$ 2,231,000
Total long-term liabilities of discontinued operations	1,712,000	2,756,000
Ending accrued balance as of December 31, 2014	$ 3,943,000

XML

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Net income	$ 4,444,000	$ 5,967,000
Other comprehensive income, net of tax
Change in fair value of marketable securities, net of tax	175,000	103,000
Adjustment for net (gains)/losses realized and included in net income, net of tax	(87,000)	(91,000)
Total change in unrealized (gains)/losses on marketable securities, net of tax	88,000	12,000
Other comprehensive income	88,000	12,000
Comprehensive income	$ 4,532,000	$ 5,979,000

XML

Recent Accounting Pronouncements

3 Months Ended

Mar. 31, 2015

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

Recent Accounting Pronouncements

3. Recent Accounting Pronouncements

We have considered all new accounting pronouncements and have concluded that there are no new pronouncements that may have a material impact on our results of operations, financial condition, or cash flows, based on current information, except for:

ASU 2014-09, Revenue from Contracts with Customers (Topic 606), requires the Company to recognize revenue for the transfer of goods or services to customers for the amount the Company expects to be entitled in exchange for those goods or services. The Company will be required to identify the contract, identify the relevant performance obligations, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when the entity satisfies a performance obligation. The provisions of this ASU are effective for interim and annual periods beginning after December 15, 2016; however, the Financial Accounting Standards Board has proposed delaying the effective date to annual periods beginning after December 15, 2017. Management is currently evaluating the effect that the provisions of ASU 2014-12 will have on the Company’s financial statements.

ASU 2014-08, Presentation of Financial Statements (Topic 205) and Property Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, raises the threshold for a disposal to qualify as a discontinued operation and requires new disclosures of both discontinued operations and certain other disposals that do not meet the definition of a discontinued operation. It is effective for annual periods beginning on or after December 15, 2014. The Company elected early option of the pronouncement and accounted for the discontinued operations of the Medifast Corporate Weight Control Center channel in accordance with these guidelines.

XML

Inventories (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Schedule of Inventory [Line Items]
Raw Materials	$ 3,692,000	$ 4,410,000
Packaging	1,105,000	920,000
Non-food Finished Goods	879,000	1,108,000
Finished Goods	8,817,000	9,689,000
Reserve for Obsolete Inventory	(307,000)	(392,000)
Inventory	$ 14,186,000	$ 15,735,000

XML

Summary of Company's Operating Results for Discontinued Operations (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue	$ 0	$ 7,296,000
Income/(loss) before income taxes from discontinued operations	45,000	(924,000)
Income tax/(benefit) provision	17,000	(346,000)
Income/(loss) from discontinued operations, net of tax	$ 28,000	$ (578,000)

XML

Stockholders' Rights Plan

3 Months Ended

Mar. 31, 2015

Stockholders' Equity Note [Abstract]

Stockholders’ Rights Plan

13. Stockholders’ Rights Plan

On August 28, 2014, the Company adopted a stockholders’ rights plan whereby the Board of Directors authorized and declared a dividend distribution of one right for each outstanding share of common stock of the Company to the stockholders of record at the close of business on September 9, 2014. The rights are not presently exercisable and remain attached to the shares of common stock until the occurrence of certain triggering events. The rights will expire on August 28, 2015, unless exercised, redeemed, or exchanged prior to that time. The Board of Directors may terminate the rights plan before the expiration date.